Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 1:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 3,322 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: saline solution (placebo) Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

Study of Dexmedetomidine in Spine Surgery

NCT01850017
View directory record Official record
Conditions
Collapse of Thoracic Vertebra, Collapse of Lumbar Vertebrae
Interventions
Dexmedetomidine
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 80 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 5, 2017 · Synced Sep 30, 2026, 1:04 PM EDT
Completed Phase 2 Interventional

Study of Responsiveness of Seven Functional Tasks in Patients With Poststroke Upper Limb Spasticity With Botulinum Toxin Type A Treatment

NCT00651690
View directory record Official record
Conditions
Stroke, Muscle Spasticity
Interventions
Botulinum Toxin Type A, Placebo
Biological
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 28, 2008 · Synced Sep 30, 2026, 1:04 PM EDT
Not yet recruiting Phase 1 Interventional

Anakinra Rescue Treatment for Moderate Asthma Attacks (ARTMA)

NCT07600190
View directory record Official record
Conditions
Asthma (Diagnosis), Persistent Asthma, Moderate Asthma Exacerbation
Interventions
Anakinra 100 Mg/0.67 Ml Inj Syringe, Saline Placebo/0.67 Ml Inj Syringe
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 30, 2026, 1:04 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001

NCT02334423
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum toxin, Type A, 0.9% sterile, unpreserved saline
Biological · Other
Lead sponsor
Evolus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Sep 30, 2026, 1:04 PM EDT
Completed Phase 1 Interventional

Phase I, Placebo-Controlled, Blinded Pilot Study of Ipratropium in Children Admitted to the ICU With Status Asthmaticus

NCT02872597
View directory record Official record
Conditions
Status Asthmaticus
Interventions
Ipratropium, 0.9% Sodium Chloride, Albuterol, corticosteroids
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
2 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Sep 30, 2026, 1:04 PM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn

NCT01720524
View directory record Official record
Conditions
Pulmonary Hypertension, Familial Persistent, of the Newborn
Interventions
placebo, iv sildenafil
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
0 Days to 4 Days
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
20
States / cities
Little Rock, Arkansas • Sacramento, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Sep 30, 2026, 1:04 PM EDT
Completed Early Phase 1 Interventional

Prevention of Post Mastectomy With Intraoperative Ketamine

NCT03090776
View directory record Official record
Conditions
Pain, Postoperative, Post-Mastectomy Chronic Pain Syndrome
Interventions
Ketamine, Placebo saline
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 30, 2026, 1:04 PM EDT
Completed Phase 2 Interventional

Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects

NCT01200420
View directory record Official record
Conditions
Hepatitis C
Interventions
miravirsen, saline
Drug
Lead sponsor
Santaris Pharma A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Sep 30, 2026, 1:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Does IV Acetaminophen Reduce Opioid Requirement in Pediatric Patients With Acute Sickle Cell Crises?

NCT03541980
View directory record Official record
Conditions
Sickle Cell Anemia Crisis
Interventions
Acetaminophen, Normal saline
Drug
Lead sponsor
Newark Beth Israel Medical Center
Other
Eligibility
4 Years to 16 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Newark, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Sep 30, 2026, 1:04 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older

NCT04537208
View directory record Official record
Conditions
COVID-19 (Healthy Volunteers)
Interventions
CoV2 preS dTM-AF03 (low-dose), CoV2 preS dTM-AF03 (high-dose), CoV2 preS dTM-AS03 (low-dose), CoV2 preS dTM-AS03 (high-dose), CoV2 preS dTM (high-dose) without adjuvant, Placebo (0.9% normal saline)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
11
States / cities
Birmingham, Alabama • Rolling Hills Estates, California • Hollywood, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Sep 30, 2026, 1:04 PM EDT
Terminated Early Phase 1 Interventional

Angiotensin-(1-7) in Peripheral Arterial Disease

NCT03240068
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Angiotensin 1-7, Saline
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
21 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Sep 30, 2026, 1:04 PM EDT
Recruiting Phase 2Phase 3 Interventional

Tranexamic Acid to Reduce Blood Loss in Spine Surgery

NCT02314988
View directory record Official record
Conditions
Spinal Injuries, Spinal Deformity
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
4
States / cities
San Francisco, California • Louisville, Kentucky • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 30, 2026, 1:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Intrafetal Digoxin as an Adjuvant for Dilation and Evacuation at 20 to 24 Weeks' Gestation

NCT03136068
View directory record Official record
Conditions
Abortion
Interventions
Digoxin, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Long Beach, California • San Francisco, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Sep 30, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults

NCT00382980
View directory record Official record
Conditions
Influenza
Interventions
Aluminum hydroxide, Inactivated Vero cell based whole virus influenza A/H5N1, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
308 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
5
States / cities
Stanford, California • Torrance, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Sep 30, 2026, 1:04 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Dexmedetomidine During Non-Invasive Positive Pressure Ventilation

NCT00871624
View directory record Official record
Conditions
Acute Respiratory Failure
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts • Winchester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Sep 30, 2026, 1:04 PM EDT
Completed Phase 2 Interventional Results available

A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection

NCT04225923
View directory record Official record
Conditions
Cytomegalovirus Disease
Interventions
NPC-21 Low dose, NPC-21 High dose, NPC-21 Placebo
Drug
Lead sponsor
Nobelpharma
Industry
Eligibility
18 Years to 76 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
14
States / cities
Phoenix, Arizona • La Mesa, California • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Sep 30, 2026, 1:04 PM EDT
Not yet recruiting Phase 2 Interventional

Botulinum Toxin Blockade of Neuronal Signals to Immune Cells as a Novel Treatment for Hidradenitis Suppurativa

NCT07756346
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Botulinum Toxin A (Allergan, Inc, Irvine CA), Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
13 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 30, 2026, 1:04 PM EDT
Completed Not applicable Interventional Results available

A Double-blind Study to Determine if Intraduodenal Indomethacin Can Decrease the Incidence of Post-ERCP Pancreatitis

NCT00727740
View directory record Official record
Conditions
Pancreatitis
Interventions
Indomethacin, Placebo suspension
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Sep 30, 2026, 1:04 PM EDT
Not listed Phase 4 Interventional

Efficacy of Intravenous Lidocaine in the Operative Management of Thyroid Surgery With Intraoperative Nerve Monitoring

NCT02479789
View directory record Official record
Conditions
Thyroidectomy, Nerve Monitoring
Interventions
Lidocaine, Placebo
Drug
Lead sponsor
Bronx-Lebanon Hospital Center Health Care System
Other
Eligibility
18 Years to 85 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Sep 30, 2026, 1:04 PM EDT
Completed Not applicable Interventional Results available

Convergence Insufficiency Treatment Study (CITS)

NCT01515943
View directory record Official record
Conditions
Convergence Insufficiency
Interventions
Active home-based computer vergence/accommodative therapy, Near target push-ups, Placebo home-based computer vergence/accommodative therapy, Placebo yoked prism flippers
Other · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
9 Years to 17 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Cranberry TWP, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Sep 30, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy Subjects

NCT01339897
View directory record Official record
Conditions
Healthy
Interventions
5 mg/N6022, Placebo, 10mg/N6022, 20mg/N6022
Drug
Lead sponsor
Nivalis Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 19, 2015 · Synced Sep 30, 2026, 1:04 PM EDT
Not yet recruiting Phase 1 Interventional

Impact of Sweeteners on the Addictive Threshold of Nicotine

NCT07771725
View directory record Official record
Conditions
Smoking ( Cigarette)
Interventions
Nicotine 0.05 mg/pulse and 0.1 mg/pulse, Saline Placebo (0.5mL injection), sucralose, Sugar syrup (Placebo)
Drug · Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
21 Years to 59 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 30, 2026, 1:04 PM EDT
Completed Not applicable Interventional Results available

A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip

NCT01618708
View directory record Official record
Conditions
Osteoarthritis, Hip
Interventions
Synvisc-One (hylan G-F 20), Placebo
Device
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
35 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
45
States / cities
Burmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Sep 30, 2026, 1:04 PM EDT
Recruiting Phase 2 Interventional

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

NCT04899908
View directory record Official record
Conditions
Brain Cancer, Brain Metastases, Melanoma, Lung Cancer, Breast Cancer, HER2-positive Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer, SRS, SRT, Whole Brain Radiation, Stereotactic Radiation, AGuIX, Nanoparticle, Cystic, Brain Tumor
Interventions
Stereotactic Radiation, AGuIX gadolinium-based nanoparticles, Placebo
Radiation · Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 30, 2026, 1:04 PM EDT